Source |21 Healthnews (Healthnews21) Original Work
Author/Han Liming
Ed.Edit/Ji Yuanyuan, Zhang Weixian
Since mid-June, Frontier Biotechnologies (688221.SH) has experienced a strong rally in the secondary market, with its share price steadily climbing from around RMB 18 per share. The stock closed at RMB 27.33 per share on July 2, hitting an intraday high of RMB 28.45, marking a cumulative gain of over 55% in just half a month.On the evening of July 2, Frontier Biotechnologies issued an announcement on abnormal stock trading fluctuations, disclosing that for three consecutive trading days—June 30, July 1, and July 2, 2026,The cumulative deviation of the company's stock closing price increase has reached 30%, triggering the criteria for identifying abnormal stock trading fluctuations.
In response to the recent unusual stock price movements, Frontier Biotechnologies stated that its current daily operations are normal and have not undergone any significant changes; there are no major events such as mergers, restructurings, or asset injections; furthermore, no market rumors were identified that could significantly impact the company’s stock trading price and require clarification from the listed company. The company’s actual controllers and other relevant parties did not engage in any buying or selling of the company’s shares during the period of unusual stock price movements. The company advises investors to view short-term market fluctuations rationally.The secondary market for the biopharmaceutical sector frequently oscillates between sharp surges and steep declines; for Frontier Biotechnologies,The company’s 2025 revenue declined year-over-year, with continuous losses throughout the year, yet its stock experienced an independent upward trend in the secondary market.Behind the Stock Price Volatility, What Is the True Quality of the Company's Fundamentals?
Single-Product Dependency, Sustained LossesFrontier Biotechnologies was established in January 2013. In June 2018, its independently developed Aikening® (Albuvirtide for Injection) received approval for market launch from the National Medical Products Administration, becoming the world’s first long-acting HIV-1 fusion inhibitor and China’s first original novel anti-AIDS drug, as well as Frontier Biotechnologies’ first product to achieve commercialization.October 2020,Frontier Biotechnologies, known as China’s “first anti-HIV stock,” listed on the SSE STAR Market at an issue price of RMB 20.5 per share.However, the company’s stock price has generally followed a volatile downward trend since its listing, with market performance falling short of expectations.In terms of performance, Aikening® was included in the National Reimbursement Drug List at the end of 2020, with the effects of volume increase and price reduction appearing simultaneously. Data shows that Aikening® achieved sales of 111,800 units in 2021, a year-on-year increase of 59.75%; however, due to the downward adjustment of procurement prices,Revenue for the same period decreased by 13.13% year-on-year to RMB 40.5029 million, while net profit attributable to parent company shareholders recorded a loss of RMB 260 million, highlighting sustained pressure on profitability.While facing pressure on its core products, Frontier Biotechnologies is simultaneously advancing the clinical development of multiple pipeline candidates, including the anti-SARS-CoV-2 investigational product FB2001 (generic name: Bofutrelvir), the investigational product FB3001 for the treatment of musculoskeletal and joint pain, the long-acting investigational lipid-lowering therapeutic FB6001, and FB4001 (a teriparatide biosimilar) for the treatment of osteoporosis.However, the 2023 annual report indicated that most pipeline candidates remain in the early to Phase II clinical stages, with commercial realization still some time away.
Against this backdrop, the oligonucleotide technology platform has become a key strategic direction for Frontier Biotechnologies in its pursuit of breakthroughs. In its 2024 annual report, the company proposed leveraging the technological synergy between oligonucleotide drugs and long-acting peptides to build an oligonucleotide R&D pipeline, with primary focus areas including IgA nephropathy, which represents a significant unmet clinical need, and dyslipidemia, which offers clear market growth potential.Currently, Frontier Biotechnologies has established a tiered pipeline of small nucleic acid therapeutics. For instance, in the field of complement-mediated diseases (including IgA nephropathy), two siRNA drugs are under development, with the most advanced candidate, FB7013, having received Investigational New Drug (IND) approval to initiate clinical trials for the treatment of primary IgA nephropathy. In the area of atherosclerotic cardiovascular disease (ASCVD), the company has developed FB7023, a dual-target small nucleic acid drug. Additionally, for metabolic dysfunction-associated steatohepatitis (MASH), the company has developed FB7033, another dual-target therapeutic agent.However, at the current stage, Frontier Biotechnologies’ operating revenue still primarily comes from Aikening®, the distributed product Valconve®, and the Far-Infrared Therapeutic Patch Xiaoyan Yitie®. The 2025 performance report shows that the company achieved a total annual operating revenue of RMB 123 million, representing a year-on-year decrease of 4.70%.Among them, Aikening® contributed RMB 105 million in sales revenue, accounting for over 85% of the total revenue.In terms of profitability, the company reported a net loss attributable to shareholders of RMB 268 million in 2025. In its annual report, Frontier Biotechnologies candidly stated that the company remains in a critical phase of expanding the commercialization of launched products and advancing its pipeline candidates in an orderly manner. It needs to continue investing in R&D expenses for multiple ongoing projects, while also allocating sustained resources to market promotion and academic research for its marketed products. Consequently, uncertainty persists regarding whether the company can achieve profitability in the short term.
Oligonucleotide Breakthrough?In response to the current situation characterized by a relatively concentrated commercial product portfolio and prolonged realization cycles for early-stage pipelines, Frontier Biotechnologies is also intensifying its business development (BD) efforts.In February this year, Frontier Biotechnologies announced that it had entered into an exclusive licensing agreement with GlaxoSmithKline (GSK), granting GSK the exclusive global rights to develop, manufacture, and commercialize two of the company’s small interfering RNA (siRNA) pipeline products.The agreement indicates that one candidate drug has entered the Investigational New Drug (IND) application stage, while the other is a preclinical candidate. Frontier Biotechnologies will be responsible for advancing the Phase I clinical trials of one product in China and completing the IND-enabling studies for the other product.As consideration for the transaction, Frontier Biotechnologies will receive a $40 million upfront payment and a $13 million near-term milestone payment, as well as up to $950 million in cumulative payments tied to development, regulatory, and commercialization milestones across the two projects, along with tiered royalty rights on the global net sales of both products.Regarding the exclusive licensing agreement for small nucleic acid therapeutics reached with GSK, Frontier Biotechnologies explicitly stated that this collaboration will help improve cash flow and optimize its financial structure. Furthermore, by leveraging GSK’s resources and expertise in global clinical development and commercialization, the company aims to accelerate the international value realization of its pipeline and facilitate the subsequent advancement of product commercialization,Lay a solid foundation for expanding global cooperation.However, from an industry perspective, compared to the “certain cash flow” of a $40 million upfront payment,The upcoming $13 million milestone payment and the $950 million milestone payment are contingent upon product development and regulatoryApproval, commercialization, and other key stagescan be gradually realized only through smooth progress, and continued attention is still required.On a global scale, as the third major class of drugs following small-molecule drugs and antibody drugs, oligonucleotide therapeutics are sparking a revolution in treatment paradigms within the pharmaceutical industry.In 2026 alone, transaction activity in the global oligonucleotide therapeutics sector has heated up significantly, with major players frequently making strategic moves.For example, in February this year, Ribo Life Science announced that it had entered into an exclusive global licensing agreement with Madrigal Pharmaceuticals, Inc., a global leader in the field of MASH. The two parties will jointly develop six innovative siRNA therapies for metabolic dysfunction-associated steatohepatitis (MASH) based on Ribo Life Science's independently developed liver-targeted RiboGalSTAR™ platform.In July, CSPC Pharmaceutical Group announced that it had entered into a collaboration, option, and license agreement with AstraZeneca to establish a strategic R&D partnership and develop novel small nucleic acid drug candidates by leveraging CSPC’s proprietary siRNA drug discovery platform and extrahepatic targeted delivery platform. Under the terms of the agreement, CSPC will receive an upfront payment of $30 million and is eligible to receive up to $540 million in potential R&D milestone payments and up to $1.2 billion in potential sales milestone payments, as well as potential single-digit royalties based on annual net sales of the relevant products.Industry insiders pointed out to reporters from 21st Century Business Herald that, based on the revolutionary performance of small nucleic acid drugs in chronic disease management, this field has become a hot spot for investment.However, as a surge of enterprises enters the field, intensifying competition, companies must rely on differentiated technological designs—such as oral delivery systems, ultra-long dosing intervals, and enhanced safety profiles—to establish competitive advantages in global business development (BD) transactions and clinical competitions.Overall, for Frontier Biotechnologies, the ability to sustain alignment between valuation and performance in the future will depend on the realization of business development (BD) milestone payments, as well as the continuous advancement of its self-developed pipeline and diversification of its revenue structure.Image/21 Gallery
Layout/Xu Qiulian
[Copyright Notice] All content in this article is copyrighted by 21st Century Business Herald. Without prior permission, it may not be reproduced, excerpted, or used in any other form.
